ALNY vs LRMR
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. LRMR: Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the underlying protein deficiency in Friedreich's ataxia.
Side-by-side fundamentals
| Metric | ALNY | LRMR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $278.40 | $3.83 | |
| Market cap as of 2026-08-01 | $36.9B | $397M | |
| P/E as of 2026-08-01 | 47.67 | n/a | |
| PEG as of 2026-08-01 | 0.75 | -0.05 | LRMR lower |
| Net margin as of 2026-08-01 | +13.5% | n/a | |
| Gross margin as of 2026-08-01 | +80.8% | n/a | |
| Operating margin as of 2026-08-01 | +16.6% | n/a | |
| ROE as of 2026-08-01 | +98.3% | -134.1% | ALNY higher |
| ROA as of 2026-08-01 | +11.8% | -96.0% | ALNY higher |
| Debt / equity as of 2026-08-01 | 2.52 | 0.00 | LRMR lower |
| Revenue growth (YoY) as of 2026-08-01 | +82.6% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +53.0% | n/a | |
| Beta as of 2026-08-01 | 0.26 | 0.75 | |
| 1-year return as of 2026-07-27 close | -15.3% | -1.3% | LRMR higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.